Showing results (1-10 of 29) with videos related to
Sort By:
Pageof 3
Canadian Journal of Microbiology|December 20, 2008
Bacterial chemotaxis differences in Escherichia coli isolated from different hostsSijana H Dzinic, Marcella Luercio, Jeffrey L RamCancer Metastasis Reviews|November 30, 2022
The vulnerable primed cancer stem cells in disguise: demystifying the role of MaspinShijie Sheng, Margarida Bernardo, Sijana H Dzinic, et al.Microbiology (Reading, England)|August 1, 2008
Variable length tandem repeat polyglutamine sequences in the flexible tether region of the Tsr chemotaxis receptor of Escherichia coliSijana H Dzinic, Meghna Shukla, Ilir Mandija, et al.Journal of Cellular Biochemistry|March 7, 2017
The Opportunity of Precision Medicine for Breast Cancer With Context-Sensitive Tumor Suppressor MaspinMargarida M Bernardo, Sijana H Dzinic, Maria J Matta, et al.Cancer Metastasis Reviews|November 29, 2018
Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature reviewShijie Sheng, M Margarida Bernardo, Sijana H Dzinic, et al.Bosnian Journal of Basic Medical Sciences|November 29, 2015
Tumor suppressor maspin as a modulator of host immune response to cancerSijana H Dzinic, Maria M Bernardo, Daniel S M Oliveira, et al.Plos One|November 27, 2013
Identification of an intrinsic determinant critical for maspin subcellular localization and functionSijana H Dzinic, Alexander Kaplun, Xiaohua Li, et al.Oncotarget|December 24, 2016
The secretion and biological function of tumor suppressor maspin as an exosome cargo proteinIvory Dean, Sijana H Dzinic, M Margarida Bernardo, et al.Investigational New Drugs|November 20, 2015
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) studyManish K Thakur, Lance K Heilbrun, Shijie Sheng, et al.Signal Transduction and Targeted Therapy|April 17, 2020
Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemiaDaniel A Luedtke, Yongwei Su, Jun Ma, et al.Pageof 3